Disease · MONDO_0005146
Comparisons in its trials156
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 156
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Brexpiprazole + Sertraline vs Sertraline + Placebo: deaths from any cause | 0 of 205 | 1 of 196 | 401 | NCT04124614 | Trial comparisons |
| Brexpiprazole + Sertraline vs Sertraline + Placebo: serious adverse events | 1 of 205 | 4 of 196 | 401 | NCT04124614 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 179 | 0 of 179 | 358 | NCT03062540 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 3 of 175 | 5 of 176 | 351 | NCT03062540 | Trial comparisons |
| Prazosin Group vs Placebo Group: serious adverse events | 18 of 152 | 17 of 152 | 304 | NCT00532493 | Trial comparisons |
| Risperidone vs Sugar Pill: serious adverse events | 16 of 133 | 10 of 134 | 267 | NCT00099983 | Trial comparisons |
| BNC210 900 mg vs Placebo: deaths from any cause | 0 of 105 | 0 of 104 | 209 | NCT04951076 | Trial comparisons |
| BNC210 900 mg vs Placebo: serious adverse events | 0 of 105 | 2 of 104 | 209 | NCT04951076 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 99 | 0 of 93 | 192 | NCT03841773 | Trial comparisons |
TNX-102 SL - TNX-102 SL vs Placebo - TNX-102 SL: Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study | 40 of 93 | 62 of 97 | 190 | NCT03110575 | Trial comparisons |
| TNX-102 SL - TNX-102 SL vs Placebo - TNX-102 SL: deaths from any cause | 0 of 93 | 0 of 97 | 190 | NCT03110575 | Trial comparisons |
| TNX-102 SL - TNX-102 SL vs Placebo - TNX-102 SL: serious adverse events | 0 of 93 | 0 of 97 | 190 | NCT03110575 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 0 of 96 | 2 of 91 | 187 | NCT03841773 | Trial comparisons |
| N-Acetylcysteine (NAC) Treatment Group vs Placebo Group: deaths from any cause | 0 of 93 | 1 of 89 | 182 | NCT02966873 | Trial comparisons |
| N-Acetylcysteine (NAC) Treatment Group vs Placebo Group: serious adverse events | 5 of 93 | 3 of 89 | 182 | NCT02966873 | Trial comparisons |
| Oxytocin vs Placebo: deaths from any cause | 0 of 92 | 0 of 88 | 180 | NCT04228289 | Trial comparisons |
| Oxytocin vs Placebo: serious adverse events | 1 of 92 | 0 of 88 | 180 | NCT04228289 | Trial comparisons |
| Losartan vs Placebo: deaths from any cause | 0 of 75 | 0 of 74 | 149 | NCT02709018 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005146/comparisons